NEURO: Neurotransmitter Systems III: Monoamines Flashcards

1
Q

What is a monoamine?

A

A monoamine is a compound having a single amine group in its molecule. Monoamines refer to the particular neurotransmitters; noradrenaline, serotonin and dopamine. These neurotransmitters are involved in mediating a wide range of physiological and homeostatic functions, which vary with the part of the brain being examined.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the 3 CNS systems that control behaviour?

A
  • The autonomic nervous system
  • Hypothalamic-pituitary neurohormones
  • Diffuse monoamine system
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the 4 main systems of the diffuse monoamine system?

A

The 4 main systems:

  • Noradrenergic Locus Coeruleus
  • Serotonergic Raphe Nuclei
  • Dopaminergic Substantia Nigra and Ventral tegmental Area
  • Cholinergic Basal Forebrain and Brain Stem Complexes.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What 4 principles do the monoamine systems have in common?

A
  • they have a small set of neurons at their core
  • they arise from the brain stem
  • one neuron influences many others
  • synapses release transmitter molecules into the extracellular fluid
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Signalling in the nervous system can be fast or slow. Describe the fast and slow signalling.

A

FAST, restricted point-to-point signalling:

  • neurotransmitters producing excitatory or inhibitory potentials
  • glutamate, GABA, ACh

SLOW transmission: Diffuse Modulatory system

  • neurotransmitters and neuromodulators
  • monoamines, peptides, ACh
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Give some examples of metabotropic receptors and their consequent actions upon stimulation.

A
  • 5-HT1: inhibits Adenylate Cyclase (AC)
  • 5-HT2: stimulate PhosphoLipase C (PLC)
  • Dopamine D1: stimulates AC
  • Dopamine D2: inhibits AC
  • Noradrenaline β: stimulates AC
  • Noradrenaline α1: stimulates PLC
  • Noradrenaline α2: inhibits AC
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the noradrenergic monoamine system.

A

It consists of noradrenergic neurons which project from the central core, the locus coeruleus (LC). They project to several areas of the brain, including:

  • the cortex
  • the amygdala
  • the hypothalamus
  • the spinal cord
  • the cerebellum
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Briefly mention some actions of noradrenaline on the body.

A
  • Noradrenaline is very important in brain arousal (via the LC) enabling us to think and take action fast.
  • Important in wakefullness
  • inhibiting sleep.
  • Exploration and mood (low NA in depression)
  • It also affects our cardiovascular system by increasing our heart rate, increasing our blood pressure, etc. It does this not only by acting on the heart muscle directly but also by acting on the cardiovascular systems in the brain.
  • When gambling/etc., we get a noradrenergic surge, which plays a role in addiction.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How is Noradrenaline synthesised?

A

Tyrosine –> DOPA (catalysed by enzyme Tyrosine hydroxylase)

DOPA –> Dopamine (catalysed enzyme by DOPA decarboxylase)

Dopamine —> Noradrenaline (catalysed enzyme by Dopamine-β-hydroxylase)

Nordrenaline can be converted to adrenaline by Phenylethanolamine N-methyltransferase, but this is irrelevant here.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How is Noradrenaline (NA) regulated?

A

NA is packed into vesicles in the pre-synaptic neuron. Upon noradrenergic neuron stimulation, NA is released into the synaptic cleft by exocytosis from the vesicles and pre-synaptic neuron. This activates the noradrenergic receptors on the post-synaptic neuron. There are also some noradrenergic neurones on the pre-synaptic neuron (e.g. α2), this is an autoreceptor and is usually inhibitory. It can regulate levels of NA via negative feedback mechanisms. Furthermore, an excess of NA can be regulated by being re-uptaken into the pre-synaptic neuron by the noradrenaline transporter. The NA will then be broken down and metabolised by an enzyme called monoamine oxidase (MAO).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the noradrenergic receptors?

A

There are α (α1 and α2) and β noradrenergic receptors. Both are GPCRs. Noradrenaline stimulates α1 and β receptors, and inhibits α2 receptors.

NA binds to α1 receptors (Gq):
activate Phospholipase C –> convert PIP2 to IP3 and DAG –> increase intracellular Ca2+ –> causing smooth muscle contraction, glycogenolysis and other various pharmacological effects.

NA binds to α2 receptors (Gi):

  • this will inhibit adenyl cyclase –> thus decease the conversion of ATP to cAMP –> inhibit smooth muscle contraction
  • it will also decrease intracellular ca2+ –> thus inhibit NA release

NA binds to the B receptor (Gs coupled):
activating adenyl cyclase –> increased ATP converted to cAMP –> increase contraction of cardiac muscle, smooth muscle relaxation, there will also be glycogenolysis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

List some drugs and their effect on noradrenaline levels.

A
  • Reserpine: depleted NA stores by inhibiting vesicular uptake. Associated with depression and to treat hypertension.
  • Amphetamine (indirect sympathomimetic): enters vesicles, displacing NA into the cytoplasm, increasing NA leakage out of the neuron. This causes a surge of NA and ‘excitement’.
  • Cocaine-blocks NA re-uptake.

Low levels of NA associated with depression. Thus increasing NA in the synaptic media (cleft) can help counter that. Anti-depressants block NA transporters. Thus increase NA in the synaptic cleft. Some drugs block the monoamine oxidase enzyme and thus cause an NA surge.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the dopaminergic (DA) monoamine pathways.

A

There are many dopaminergic pathways. These include the:

  • NIGROSTRIATAL PATHWAY: the dopaminergic cell bodies are located in the substantia nigra. They project to the striatum where dopamine is released. This is important for the initiation/control of voluntary movement. Degeneration of these neurones are associated with movement impairment and diseases such as Parkinson’s Disease, dyskinesis and Dyskinesia (movement disorders). Parkinson’s disease is characterised by deficits of the dopamine receptors and degeneration of precursors (L-dopa).
  • MESOLIMBIC PATHWAY: The dopaminergic cell bodies are located in the ventral tegmental area (area) and project DA to the various regions including: - the Nucleus Accumbens –> involved in reward and pleasure. - the Amygdala –> involved in emotionality - the Hypothalamus –> involved in memory and learning. Hyperactivity of the mesolimbic pathway is associated with positive symptoms of schizophrenia such as hallucinations.
  • MESOCORTICAL PATHWAY: Dopaminergic neurons project from the ventral tegmental area directly to the frontal cortex - involved in higher cognitive functions.
  • TUBERO-HYPOPHYSEAL PATHWAY: Dopaminergic neurones project DA from the hypothalamus to the pituitary via the hypophyseal circulation. In the pituitary it will bind to the dopamine D2 receptor and a inhibit prolactin release. Dopamine receptors are also located at the chemoreceptor trigger zone, dopamine is thus also involved in emesis (vomiting). DA is also involved in ADHD. prolactin secretion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How is dopamine synthesised?

A

Tyrosine –> DOPA (catalysed by enzyme Tyrosine hydroxylase)

DOPA –> Dopamine (catalysed enzyme by DOPA decarboxylase)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe dopamine regulation.

A

In the pre-synaptic neuron L-dopa (DA precursor) is converted to DA via dopa decarboxylase. DA gets into the DA vesicles and is released into the synaptic cleft following stimulation of the neuron. The DA can then activate the Dopamine receptors on the post synaptic neuron - D1 and D2. D2 is also found on pre-synaptic neurons and can act as an autoreceptor, thus inhibiting DA release from the pre-synaptic neuron.

It is very important to regulate levels of DA as high levels can cause psychosis and low levels can cause movement impairment.

An excess of DA in the synaptic cleft be re-uptaken into pre-synaptic neuron via DA transporters. This is then broken down into its metabolites by Monoamine Oxidase type B (MAOb). To increase dopamine levels (e.g. for Parkinson’s disease), more L-dopa (precursor) can be administered, the MAOb enzyme can be inhibited and the DA transporter can be inhibited.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the dopamine receptors.

A

There are 2 kinds of dopamine receptors (and 5 receptor subtypes):

  • D1-LIKE RECEPTORS: D1, D5
  • D2-LIKE RECEPTORS: D2, D3, D4

Both types are GPCRs with 7 transmembrane domains, with N terminals found extracellular and C terminals found intracellularly. D1 receptors are linked to αGs subunits, and thus are excitatory. D2 receptors are linked to αGi subunits, and thus are inhibitory. The D1-like receptors stimulate adenyl cyclase thus increase cAMP activity thus increase PKA activity which phosphorylates various proteins including the DARPP-32 protein (important dopamine signaling molecule.) D2-like receptors inhibit adenyl cyclase thus decrease cAMP and PKA activity. D2-like receptors also increase opening of potassium channels and inhibit calcium channels leading to inhibition of neurotransmitter release.

17
Q

Describe the serotonergic monoamine system.

A

Serotonin is released from serotonergic neurones which project from the raphe nucleus. This is where the serotonergic neuron cell bodies are found. They project to different areas of the brain, such as:

  • the cortex
  • the striatum (important for movement)
  • the thalamus (important for relay of information in the brain)
  • the hypothalamus (important for thermoregulation sleep regulation, endocrine control and appetite regulation)
  • the hippocampus (important in learning and memory)
  • the amygdala (important for emotionality)
  • the cerebellum (important in motor coordination and to the spinal cord
  • involved in pain modulation).
18
Q

Briefly mention some actions of serotonin on the body.

A
  • increased 5-HT in the cortex causes heightened perceptions
  • increased 5-HT in the hypothalamus causes reduced appetite
  • increased 5-HT in the amygdala causes elevated mood
  • increased 5-HT in the spinal cord will suppress pain.

Ecstasy (mdma) is a drug that increases serotonin levels.

19
Q

How is serotonin synthesised?

A

Tryptophan is the precursor of serotonin. It can only be obtained from food as the body cannot manufacture it.

Tryptophan is converted to 5-hydroxytryptophan, catalysed by enzyme tryptophan hydroxylase.

5-hydroxytryptophan is converted to 5-hydroxytryptamine, or serotonin, catalysed by enzyme dopa decarboxylase.

Serotonin can be metabolised by MAO.

20
Q

Describe serotonin (5HT) regulation.

A

Serotonin is packaged into vesicles in the pre-synaptic neuron and can be released from the synaptic bouton via exocytosis into the synaptic cleft. Serotonin can then activate the post synaptic neuron serotonin receptors (there are 14 subtypes: 13 GPCRs and 1 LGICR - 5-HT3).

The 5HT1D receptor is an autoreceptor on the pre-synaptic neuron, this causes the inhibition of serotonin release from the pre-synaptic neuron.

Too high levels of 5HT are associated with serotonin syndrome which can induce seizures, and CVS collapse. Too low levels of 5HT is associated with depression.

Excess serotonin in the synaptic cleft is re-uptaken by the 5-HT transporter. It is is then broken down and metabolised by MAO.

21
Q

How can serotonin drugs be used to treat depression?

A

Drugs that block serotonin reuptake transporters would be used. Drugs that inhibit monoaminoxidase could also be used. Both of these mechanisms ensure that there is more serotonin in the synaptic cleft.

22
Q

Describe the monoamine serotonin receptors and some of their functions.

A

There are 14 5-HT receptors consisting of 14 subtypes (all of which are GPCRs except for the LGICR 5-HT3). The 5-HT receptors:

  • 5-HT1 inhibitory, limbic system – involved mood, migraine
  • 5-HT2 (5-HT2A), excitatory, involved in hallucinogenic, limbic system & cortex
  • 5-HT3 excitatory, medulla – involved in vomiting
  • 5-HT4 presynaptic facilitation (ACh) – involved in cognitive enhancement
  • 5-HT6 and 5-HT7 – involved in cognition and sleep

Termination: MAO, neuronal uptake

Function / disorders:

  • Mood (anxiety/depression)
  • Psychosis (5-HT antagonism antipsychotic)
  • Sleep/wake (5-HT linked to sleep, 5-HT2 antagonists inhibit REM sleep)
  • Feeding behaviour (5HT2A antagonist increase appetite, weight gain; antidepressants decrease appetite
  • Pain, migraine (5-HT inhibits pain pathway, synergistic with opioids)
  • Vomiting
23
Q

Define autoreceptors. List the transmitter and the corresponding autoreceptor.

A

Autoreceptors: inhibit cell firing and transmitter release at the terminal regions.

5-HT: 5-HT1A (cell body) and 5-HT1D (post-synaptically)

Dopamine: D2 or D3

Noradrenaline: α2

24
Q

Define reuptake transporters. List some transporters and their reuptake sites.

A

Transporters usually take the neurotransmitter back up into the pre-synaptic terminal. The transporters and their reuptake sites:

Dopamine - DAT (on dopamine neuron)

5-HT - SERT (on H-HT neurons)

NA - NET (on noradrenaline neurons)

Glutamate - EAAT1 (mostly on astrocytes)

Dopamine - vMAT2 (into vesicles)

25
Q

What is the structure of the monoamine transporters?

A

They have 12 transmembrane domains, of which both ends are intracellular. They pump monoamines in neurones. Examples would be DA, NA and 5HT transporters.

26
Q

Describe the different acetylcholine pathways in the brain.

A

Cholinergic neurones project from the nucleus basalis where the cell body is found to different regions of the brain including the cortex. Others project from the septum to the hippocampus. Others project from the substantia nigra to the thalamus. There are also a lot of interneurones which are found in the striatum.

27
Q

What are some of the main functions and risks associated with Acetylcholine in the brain?

A

ACh is involved in:
- Memory, learning.

Degeneration of cholinergic neurons is associated with alzheimer’s and dementia.

  • Motor control (striatum)
  • Reward
  • Arousal
  • Alzheimer’s
  • Pain
  • Addiction
  • Epilepsy (nAChR genes)
  • Schizophrenia
  • ADHD
  • depression
  • anxiety
28
Q

Describe the synthesis and action of acetylcholine.

A

Acetyl CoA and choline are combined to form acetylcholine, which is packaged into vesicles and released (exocytosis). When released, they act on their receptors.

There are 2 kinds of receptors:

  • muscarinic (G protein-coupled)
  • nicotinic (ionotropic)

There are also some receptors on the synaptic bouton (autoreceptors).

29
Q

How do we regulate the amount of acetylcholine in the synapse?

A

We can regulate the amount of acetylcholinesterases, which break down acetylcholine into acetate and choline (the choline is reabsorbed via a transporter called choline carrier and is recycled).

To increase the amount/activity of ACh, we would use an acetylcholinesterase inhibitor, which will mean less ACh is being broken down. Too low ACh can lead to cognitive decline (e.g. cause Alzheimer’s disease.)

30
Q

Noradrenaline Summary

A

The main action inhibitory but there is also excitatory action.

Termination: neuronal uptake and MAO Main cell body in locus coeruleus.

NAergic neurons active when ‘awake’.

Amphetamine - increases alertness and exploratory behaviour.

There is a high density in the brainstem, hypothalamus and medial temporal lobe.

Functions:

  • Arousal, wakefullness, exploration and mood (low NA in depressed patients)
  • Blood pressure regulation, (antihypertensive e.g. clonidine α2) - Addiction/gambling
31
Q

Dopamine Summary

A
  • Inhibits central neurons (K+ channels)
  • D1 (D1 & D5) and D2 (D2, D3, D4) receptors.
  • D1 and D2 receptors in striatum, limbic system, thalamus & hypothalamus
  • D3 receptors in limbic system NOT striatum
  • D4 receptors in cortex & limbic system

Termination: MAO, neuronal uptake Main pathways

  • Substantia nigra to basal ganglia (Parkinson’s disease)
  • Midbrain to limbic cortex (schizophrenia)

Functions / disorders: Movement, addiction, stereotypy, hormone release, vomiting.

32
Q

Serotonin Summary

A

There are 14 5-HT receptors consisting of 14 subtypes (all of which are GPCRs except for the LGICR 5-HT3).

The 5-HT receptors:

  • 5-HT1 inhibitory, limbic system – involved mood, migraine
  • 5-HT2 (5-HT2A), excitatory, involved in hallucinogenic, limbic system & cortex
  • 5-HT3 excitatory, medulla – involved in vomiting
  • 5-HT4 presynaptic facilitation (ACh) – involved in cognitive enhancement
  • 5-HT6 and 5-HT7 – involved in cognition and sleep

Termination: MAO, neuronal uptake

Function / disorders:

  • Mood (anxiety/depression)
  • Psychosis (5-HT antagonism antipsychotic)
  • Sleep/wake (5-HT linked to sleep, 5-HT2 antagonists inhibit REM sleep)
  • Feeding behaviour (5HT2A antagonist increase appetite, weight gain; antidepressants decrease appetite
  • Pain, migraine (5-HT inhibits pain pathway, synergistic with opioids)
  • Vomiting
33
Q

Acetylcholine Summary

A
  • Abundant in basal forebrain, hippocampus and striatum
  • Termination – acetylcholinesterase (AChE)
  • ACh excitatory neurotransmitter:
  • Nicotinic (ionotropic / fast)
  • Muscarinic (G-protein coupled / slow)
  • M1 excitatory ( M1 receptors in dementia)
  • M2 presynaptic inhibition (inhibit Ach release)
  • M3 excitatory glandular/smooth muscle effects (side effects)
  • M4 and M5 function not well known
34
Q

List some other transmitters/modulator substances.

A

HISTAMINE:

  • H1 (arousal) and H3 (presynaptic/constitutively active)
  • functions: sleep/wake, vomiting

PURINES:

  • adenosine (receptors: A1, A2a/2b) and ATP (receptor: P2x)
  • functions: sleep, pain, neuroprotection, addiction, seizures, ischaemia, anticonvulsant

NEUROPEPTIDES:

  • opioid peptides (μ, δ, κ) –> reward effect
  • tachykinins (substance P [NK1], neurokinin A [NK2] and neurokinin B [NK3])
  • functions: pain

LIPID MEDIATORS:

  • products of conversion of eicosanoids to endocanabinoids
  • act on CB1 (inhibit GABA, glutamate release)
  • involved in vomiting (CB1 agonist block it, MS, pain, anxiety, weight loss/rimonoabant CB1 antagonist)

MELATONIN:

  • MT1, MT2 receptors
  • involved in sleep regulation, circadian rhythmicity, agonists for jet lag and insomnia
35
Q

List the opioid peptide families and the opioid receptors they act on.

A

There are 4 opioid peptide families.

= Proopioimelanocortin (gives rise to β-endorphins) acts on MOP (μ) and DOP (δ).

  • Proenkephalin (giving rise to at least 4 enkephalins) acts on DOP (δ).
  • Prodynorphin (giving rise to two dynorphins and two neo-endorphins) acts on KOP (κ).
  • Pronociceptin (giving rise to nociceptin and OFQ) acts on NOP (ORL 1).
36
Q

How do psychoactive drugs induce their pleasurable effects.

A

All drugs of abuse including nicotine cannabis, heroin,, cocaine, amphetamine, alcohol, ecstasy etc induce their hedonic (pleasurable) effects by activating the mesolimbic dopaminergic system (dopaminergic neurons project from the ventral tegmental area (VTA) to the nucleus accumbens where DA is released). Thus dopamine increases causing the feeling of highs, and reward/pleasure.

37
Q

Describe amphetamine and its actions.

A

Examples of amphetamine-like drugs that are used recreationally are methylphenidate and MDMA. They release cystolic monoamines (DA) by displacing them from their vesicles thus increasing DA levels. Their prolonged use can be neurotoxic. It causes the degeneration of amine-containing nerve terminals and, ultimately, cell death.

Pharmacological effects:

  • increased alertness and locomotor stimulation (increased aggression)
  • euphoria/excitement
  • sterotyped behaviour
  • anorexia
  • decreased physical and mental fatigue (improves monotonous tasks)
  • peripheral sympathomimetic actions (increased BP and decreased gastric mobility)
  • confidence improves/lack of tiredness

It can be used therapeuticaly to treat ADHD (methylphenidate), as appetite suppressants and to treat narcolepsy.

38
Q

Describe cocaine and its actions.

A

Cocaine blocks catecholamine (DA transporter) reuptake. It increases dopamine and has a stimulant effect.

Pharmacological effects:

  • euphoria
  • locomotor stimulation (fewer sterotypes behaviours than amphetamine)
  • heightened pleasure (lower tendency for delusions, hallucinations and paranoia)

Pharmacokinetics:

  • HCl salt, inhaled and i.v. administration (nasal inhalation is less intense, but leads to the necrosis of nasal mucosa)
  • Freebase form (‘crack’) is smoked, and can be as intense as the i.v. route
39
Q

Describe the effects of drug abuse on other diffuse modulatory systems (i.e. other than DA).

A

MDMA (ecstasy):

  • Inhibits monoamine transporters (mainly 5-HT)
  • Large increase in 5-HT (followed by depletion)
  • Increase 5-HT linked to psychotomimetic effects
  • Increase DA linked to euphoria (followed by rebound dysphoria)

LSD, Psylocybin:
- Hallucinogenic effect by acting on 5-HT2 receptors.

Psychostimulants

  • Increase 5HT and NA
  • Cocaine blocks transporters DAT, NET, SERT —> preventing breakdown.